Karima Yataghene

Karima Yataghene

Auto-generated profile, based on publicly available information

Karima Yataghene

Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2004 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
BKBrian H. Kushner
Brian H. Kushner
KKKim Kramer
Kim Kramer
MLMichael P. LaQuaglia
Michael P. LaQuaglia
Shakeel ModakShakeel Modak
Shakeel Modak
KYKarima Yataghene
Karima Yataghene
NCNai-Kong V. Cheung
Nai-Kong V. Cheung
Purpose: We previously reported a high response rate with a dose-intensive chemotherapy regimen in 24 children with high-risk neuroblastoma (NB). We now describe similar results with changes that reduce toxicity (fewer cycles, less vincristine, use of granulocyte colony-stimulating factor). Patients and Methods: Eighty-seven consecutive newly diagnosed children with high-risk NB underwent induction that initially had seven cycles (57 patients) but was later limited to five (30 patients). Cycles 1, 2, 4, and 6 used cyclophosphamide (140 mg/kg)/doxorubicin (75 mg/m2)/vincristine (0.15 mg/kg in the first 27 patients, 0.067 mg/kg subsequently). Cycles 3, 5, and 7 used cisplatin (200 mg/m2)/etoposide (600 mg/m2). Tumor resection followed a minimum of three cycles. The induction was eventually modified to include anti-GD2 immunotherapy after each of the last three cycles (38 patients). Results: Bone marrow disease resolved in 70 (91%) of 77 patients and was not detected pre- and postinduction in 10 patients. After cycle 3 or 4, 86% of primary tumors were more than 50% smaller. Postinduction metaiodobenzylguanidine scans showed normal radiotracer distribution in metastatic sites in 74 (87%) of 85 patients. Overall results were: 68 (79%) complete/very good partial responses (CR/VGPR); 14 (16%) partial responses (PR); three (3%) less than PR; one (1%) death from infection; and one patient not assessable for response. Five cycles yielded a CR/VGPR rate of 83%, compared with a 77% rate from seven cycles. Side effects were myelosuppression, mucositis, and hearing deficits; neurotoxicity was insignificant with the lower vincristine dosage. Four patients (each received seven cycles) developed myelodysplasia/leukemia. Conclusion: Five cycles of this induction regimen, plus surgery, suffice to achieve CR/VGPR in ≈80% of children with high-risk NB.

26 November 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
BKBrian H. Kushner
Brian H. Kushner
IOIrina Ostrovnaya
Irina Ostrovnaya
ICIrene Y. Cheung
Irene Y. Cheung
DKDeborah Kuk
Deborah Kuk
Shakeel ModakShakeel Modak
Shakeel Modak
NCNai-Kong V. Cheung
Nai-Kong V. Cheung
Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-G D2 immunotherapy and isotretinoin

19 March 2015 in OncoImmunology
Verified
Journal Article
Open access
BKBrian H. Kushner
Brian H. Kushner
IOIrina Ostrovnaya
Irina Ostrovnaya
ICIrene Y Cheung
Irene Y Cheung
DKDeborah Kuk
Deborah Kuk
KKKim Kramer
Kim Kramer
NCNai-Kong V Cheung
Nai-Kong V Cheung
Relapse of high-risk neuroblastoma (HR-NB) is deemed invariably fatal yet increasing numbers of HR-NB patients achieve a second complete/very good partial remission (CR/VGPR), hence the urgency to find a successful consolidative therapy. Identifying efficacy in patients without assessable disease, however, is problematic. We report the first study providing outcome data for this group of patients with poor prognosis. To prevent another relapse, HR-NB patients in second or later CR/VGPR received the anti-GD2 murine antibody 3F8 plus granulocyte-macrophage colony-stimulating factor plus isotretinoin in a Phase II trial. Upon meeting the target aim for progression-free survival (PFS) in the initial cohort of 33 patients, the trial was amended to allow patients who developed human anti-mouse antibody (HAMA) to receive rituximab to ablate HAMA with or without low-dose maintenance chemotherapy until immunotherapy could resume. For the total of 101 study patients, 5-year PFS and overall survival (OS) rates were 33% ± 5% and 48% ± 5%, respectively. Among the 33 long-term progression-free survivors, 19 had MYCN amplification, 19 had previously received anti-GD2 immunotherapy plus isotretinoin (as first-line therapy), and 15 never received maintenance chemotherapy. In a multivariate analysis of prognostic factors, only absence of minimal residual disease in bone marrow after 2 cycles of immunotherapy and before initiation of isotretinoin or anti-HAMA therapy was significantly favorable for both PFS and OS. Therefore, long-term PFS is possible for HR-NB patients who achieve at least a second CR/VGPR and receive consolidation that includes anti-GD2 immunotherapy plus isotretinoin, even if the patients received these biological treatments before relapse. Results from this prospective study will aid in the development of future Phase II studies for this growing ultra high-risk patient population.

1 April 2014 in Cancer
Verified
Journal Article
Open access
PDF file
BKBrian H. Kushner
Brian H. Kushner
Shakeel ModakShakeel Modak
Shakeel Modak
KKKim Kramer
Kim Kramer
MLMichael P. LaQuaglia
Michael P. LaQuaglia
KYKarima Yataghene
Karima Yataghene
NCNai‐Kong V. Cheung
Nai‐Kong V. Cheung
BACKGROUND: The authors exploited a large database to investigate the outcomes of patients with high‐risk neuroblastoma in the contemporary era.METHODS: All patients with high‐risk neuroblastoma aged 18 months with MYCN‐nonamplified [MYCN(−)] stage 4 disease.RESULTS: A complete response/very good partial response (CR/VGPR) to induction was correlated with significantly superior event‐free survival (EFS) (P < .001) and overall survival (OS) (P < .001) compared with a partial response or less. Patients with MYCN(+) and MYCN(−) disease had similar rates of CR/VGPR to induction (P = .366), and those with MYCN(+) and MYCN(−) disease who attained a CR/VGPR had similar EFS (P = .346) and OS (P = .542). In contrast, only MYCN(+) patients had progressive disease as a response to induction (P < .001), and early death from progressive disease (<366 days after diagnosis) was significantly more common (P < .001) among those with MYCN(+) disease. Overall, among patients who had a partial response or less, MYCN(+) patients had significantly inferior EFS (P < .001) and OS (P < .001) compared with MYCN(−) patients, which accounted for the significantly worse EFS (P = .008) and OS (P = .002) for the entire MYCN(+) cohort versus the MYCN(−) cohort.CONCLUSIONS: Patients with MYCN(−), high‐risk neuroblastoma display a broad, continuous spectrum with regard to response and outcome, whereas MYCN(+) patients either have an excellent response to induction associated with good long‐term outcome or develop early progressive disease with a poor outcome. This extreme dichotomy in the clinical course of MYCN(+) patients points to underlying biologic differences with MYCN(+) neuroblastoma, the elucidation of which may have far‐reaching implications, including improved risk classification at diagnosis and the identification of targets for treatment. Cancer 2014;120:2050–2059. © 2014 American Cancer Society.

15 January 2009 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
BKBrian H. Kushner
Brian H. Kushner
KKKim Kramer
Kim Kramer
Shakeel ModakShakeel Modak
Shakeel Modak
LQLi‐Xuan Qin
Li‐Xuan Qin
KYKarima Yataghena
Karima Yataghena
NCNai-Kong Cheung
Nai-Kong Cheung

31 January 2011 in European Journal of Cancer
Verified
Journal Article
Closed access
BKBrian H. Kushner
Brian H. Kushner
KKKim Kramer
Kim Kramer
Shakeel ModakShakeel Modak
Shakeel Modak
KYKarima Yataghene
Karima Yataghene
NCNai-Kong Cheung
Nai-Kong Cheung